Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
US Stocks Alert: GeneDx Holdings Surges on November 18 After CEO Appointment, BTIG Reiterates Buy Rating, and Gene Testing Updates

US Stocks Alert: GeneDx Holdings Surges on November 18 After CEO Appointment, BTIG Reiterates Buy Rating, and Gene Testing Updates

Bitget异动解读Bitget异动解读2026/11/18 19:05
Show original

GeneDx Holdings surged on November 18: Analysis

Keywords: CEO appointment, BTIG reiterates buy, genetic testing

1. On November 18, GeneDx announced the appointment of Everett Cunningham as Chief Executive Officer and Director, expected to take effect no later than December 15. He previously served as President and CEO of Quanterix, Chief Commercial Officer of Illumina, and Chief Commercial Officer of Exact Sciences, with over 35 years of business leadership experience in diagnostics, genomics, medical technology, and pharmaceuticals.

2. On November 18, BTIG analyst Mark Massaro reiterated a buy rating on GeneDx Holdings and maintained a target price of $85. The company focuses on rare disease diagnostics, provides exome and genome testing, and possesses a rare disease genomic dataset.

(Disclaimer: This content is compiled and summarized by AI technology from publicly available information, for reference only and does not constitute investment advice.)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!